Search hospitals

>

Wisconsin

>

Madison

University of Wisconsin

Claim this profile

Madison, Wisconsin 53792

Global Leader in Breast Cancer

Global Leader in Cancer

Conducts research for Lung Cancer

Conducts research for Prostate Cancer

Conducts research for Solid Tumors

952 reported clinical trials

127 medical researchers

Photo of University of Wisconsin in Madison

Summary

University of Wisconsin is a medical facility located in Madison, Wisconsin. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Prostate Cancer, Solid Tumors and other specialties. University of Wisconsin is involved with conducting 952 clinical trials across 1,757 conditions. There are 127 research doctors associated with this hospital, such as Kenneth B. De Santes, Nataliya V. Uboha, Kari B. Wisinski, and Dustin Deming, M.D..

Area of expertise

1

Breast Cancer

Global Leader

University of Wisconsin has run 78 trials for Breast Cancer. Some of their research focus areas include:

Stage IV
HER2 negative
ER positive
2

Cancer

Global Leader

University of Wisconsin has run 77 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage III
MDM2 positive

Top PIs

Clinical Trials running at University of Wisconsin

Multiple Myeloma

Prostate Cancer

Breast Cancer

Brain Tumor

Smoking Cessation

Cystic Fibrosis

Stroke

Atrial Fibrillation

Idiopathic Pulmonary Fibrosis

Lung Cancer

Image of trial facility.

Teclistamab + Lenalidomide

for Multiple Myeloma

This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.

Recruiting

3 awards

Phase 3

5 criteria

Image of trial facility.

Iberdomide Combo

for Multiple Myeloma

Similar to the paradigm established in other hematologic malignancies that are considered curable, the achievement of MRD(-) status is necessary for long term disease control in MM. The fact that the majority of patients remain MRD (+) after induction therapy and AHCT points to the opportunity to deploy novel agents with complementary mechanism of action and favorable toxicity profile to reach and maintain MRD (-) status. Given its favorable toxicity profile, the convenience of oral administration, and compelling single agent activity even in heavily pretreated MM, iberdomide is likely amenable to long term therapy in patients with high-risk of relapse/progression identified by the persistence of MRD(+). The investigators intend to develop combination(s) of iberdomide with other agents with complementary mechanism of action in the consolidation setting post AHCT in order to achieve and sustain MRD (-).

Recruiting

3 awards

Phase 1 & 2

14 criteria

Image of trial facility.

Iberdomide vs Lenalidomide

for Multiple Myeloma

This trial is testing two treatments, iberdomide and lenalidomide, to see which one is better at preventing cancer from coming back in patients with newly diagnosed multiple myeloma after a stem cell transplant. These treatments help the immune system fight off cancer cells. Lenalidomide has been used for the treatment of multiple myeloma, showing effectiveness and improving survival outcomes.

Recruiting

2 awards

Phase 3

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at University of Wisconsin?

Where is University of Wisconsin located?

Who should I call to ask about financial aid or insurance network?

What insurance does University of Wisconsin accept?

What awards or recognition has University of Wisconsin received?